Skip to main content

Table 3 Clinicopathological results of two groups

From: The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study

Parameter

SOX (n, %)

PTXS (n, %)

P value

Lauren's classification

  

0.052

 Intestinal

42 (54.5)

7 (26.9)

 

 Mixed

22 (28.6)

12 (46.2)

 

 Diffuse

13 (16.9)

7 (26.9)

 

Extent of surgery

  

1.000

 R0

72 (93.5)

24 (92.3)

 

 R1

5 (6.5)

2 (7.7)

 

Nerve invasion

  

0.227

 Yes

46 (59.7)

12 (46.2)

 

 No

31 (40.3)

14 (53.8)

 

Vessel invasion

  

0.023

 Yes

52 (67.5)

11 (42.3)

 

 No

25 (32.5)

15 (57.7)

 

pT stage

  

0.015

 T0

4 (5.2)

0 (0.0)

 

 T1

5 (6.5)

0 (0.0)

 

 T2

9 (11.7)

1 (3.8)

 

 T3

43 (55.8)

12 (46.2)

 

 T4

16 (20.8)

13 (50.0)

 

pN stage

  

0.483

 N0

37 (48.0)

9 (34.6)

 

 N1

12 (15.6)

4 (15.4)

 

 N2

17 (22.1)

6 (23.1)

 

 N3

11 (14.3)

7 (26.9)

 

ypTNM

  

0.143

 0

4 (5.2)

0 (0.0)

 

 I

9 (11.7)

1 (3.8)

 

 II

34 (44.2)

10 (38.5)

 

 III

30 (38.9)

15 (57.7)

 

Harvested lymph nodes

  

0.120

Median (range)

26 (12–80)

32 (14–60)

 

TRG

  

0.317

 Grade 0

4 (5.2)

0 (0.0)

 

 Grade 1

7 (9.1)

2 (7.7)

 

 Grade 2

27 (35.1)

7 (26.9)

 

 Grade 3

39 (50.6)

17 (65.4)

 
  1. TRG Tumor regression grade, SOX Oxaliplatin plus S-1, PTXS Paclitaxel plus S-1, CI Confidence interval